The Pharmacovigilance Final Rule on IND Safety Reporting
August 16 - 17, 2016 - Washington MA USCBI
cbireg@cbinet.com
Phone:339-298-2100
With the recently released Final Rule for IND Safety Reporting Requirements, it is critical for industry sponsors to begin implementing systematic approaches to detect and report serious and adverse reactions for the enhanced safety of patients in clinical trials. Join us at CBI’s Pharmacovigilance Final Rule Summit on IND Safety Reporting to demystify this final rule, learn to accurately and rapidly report to the FDA, minimize uninformative reports and enhance the reporting of meaningful and interpretable information.
This website uses cookies to ensure you get the best experience on our website. Learn more